Studies | EBMT

Top

Study type

Disease

Group

Type of transplant / Cell therapy

Text

Language

Fréquence des incompatibilités HLA dans les greffes de cellules hématopoïétiques à partir de donneurs non apparentés

Études rétrospectives

Toutes les maladies

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type of treatment

Allogénique - Non apparentée

Principal investigator

Esteban Arrieta Bolaños

Impact of fludarabine dose modification in conditioning regimen for CAR T-cell therapy

Retrospective Studies

Non-Hodgkin’s Lymphoma (NHL)

Acute Lymphatic Leukaemia (ALL)

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type of treatment

Principal investigator

Guillaume Dachy

Survey on the organization and techniques of ATMP facilities by DARE-NL, EBMT, T2Evolve, and NXTGEN-HIGHTECH - a GoCART-coalition initiative

Closed Survey/Study

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type of treatment

Cellular therapies (other than DLI)

Principal investigator

Infections following CAR-T therapy. A retrospective collaborative study between the Infectious Diseases Working Party (IDWP), the Cellular Therapy and Immunobiology Working Party (CTIWP), the Transplant Complications Working Party (TCWP) of the EBMT, the European Hematology Association (EHA), and the Medical College of Wisconsin.

Closed Survey/Study

Non-Hodgkin’s Lymphoma (NHL)

Acute Lymphatic Leukaemia (ALL)

GoCART Coalition

Infectious Diseases Working Party (IDWP)

Cellular Therapy & Immunobiology Working Party (CTIWP)

Transplant Complications Working Party (TCWP)

Type of treatment

Principal investigator

Autoimmune and autoinflammatory complications after CAR-T cell therapy - a joint study on behalf of the EBMT - ADWP, CTIWP and TCWP

Retrospective Studies

Acute Lymphatic Leukaemia (ALL)

Multiple Myeloma (MM) or other Plasma Cell Disorder (PCD)

Non-Hodgkin’s Lymphoma (NHL)

GoCART Coalition

Autoimmune Diseases Working Party (ADWP)

Cellular Therapy & Immunobiology Working Party (CTIWP)

Transplant Complications Working Party (TCWP)

Type of treatment

Principal investigator

Role of HLA Evolutionary Divergence in Mismatched Unrelated Donor Hematopoietic Cell Transplantation for Malignant Hematological Disorders

Retrospective Studies

Acute Lymphatic Leukaemia (ALL)

Acute Myeloid Leukaemia (AML)

Myelodysplastic (MDS) or MDS/MPN

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type of treatment

Principal investigator

Simona Pagliuca

Association between HLA evolutionary divergence and leukemia relapse after allogeneic SCT from 10/10 HLA matched related/unrelated donor

Retrospective Studies

Acute Myeloid Leukaemia (AML)

Acute Lymphatic Leukaemia (ALL)

Myelodysplastic (MDS) or MDS/MPN

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type of treatment

Principal investigator

Pietro Crivello, Pietro Merli

Graft Engineering for allogeneic hematopoietic stem cell transplantation (HSCT) and modified donor lymphocyte infusion (DLI)

Closed Survey/Study

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type of treatment

Principal investigator

Moniek de Witte

Intrabone infusion of a single umbilical cord blood unit in adults with hematological disease: a Eurocord, CTIWP-EBMT Analysis

Retrospective Studies

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type of treatment

Principal investigator

Jacopo Peccatori

CAR-T Data Collection Initiative

Post Authorization Safety (PAS) Studies

Acute Lymphatic Leukaemia (ALL)

Non-Hodgkin’s Lymphoma (NHL)

Multiple Myeloma (MM) or other Plasma Cell Disorder (PCD)

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type of treatment

Principal investigator